June 1, 2022
June 1, 2022 – The U.S. FDA has approved Beovu® (brolucizumab-dbll) 6mg, made by Novartis, to treat diabetic macular edema (DME). DME is a leading cause of blindness
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
International Medical Insurance
May 31, 2022
May 31, 2022 – Evrysdi® (risdiplam) has received expanded approval to treat spinal muscular atrophy (SMA) in patients of all ages. It was previously indicated for
May 27, 2022
May 27, 2022 – Bristol Myers Squibb's Opdivo® (nivolumab) has received two new indications to treat esophageal squamous cell carcinoma (ESCC)
May 27, 2022
May 27, 2022 – Amneal Pharmaceuticals and Kashiv Biosciences have received FDA approval for Fylnetra® (pegfilgrastim-pbbk), a biosimilar of Amgen's Neulasta®
May 25, 2022
May 25, 2022 – The U.S. FDA has approved Tibsovo® (ivosidenib – Servier) for use in combination with
azacitidine to treat newly diagnosed IDH1-mutated acute myeloid
May 24, 2022
May 24, 2022 – Vtama® (tapinarof) 1% cream has been approved to treat plaque psoriasis in adults. Vtama is the first novel topical treatment for plaque psoriasis to receive FDA
May 24, 2022
May 24, 2022 – The U.S. FDA has approved Tyvaso DPITM (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH; WHO Group 1)
May 23, 2022
May 23, 2022 – Teva Pharmaceuticals has recalled one lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure during routine stability testing.